Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Reaches New 52-Week High – Still a Buy?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF)’s stock price reached a new 52-week high during trading on Monday. The company traded as high as $51.05 and last traded at $51.05, with a volume of 100 shares. The stock had previously closed at $46.00.

Analyst Ratings Changes

Several analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Wednesday, October 28th. Deutsche Bank restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Pareto Securities raised shares of Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a report on Tuesday, October 27th. Finally, Nordea Equity Research downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, October 22nd. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Swedish Orphan Biovitrum currently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

The firm has a 50-day moving average of $45.93 and a two-hundred day moving average of $44.57. The firm has a market capitalization of $18.17 billion, a P/E ratio of 25.40 and a beta of 0.48. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.